CN1640408A - Multifunctional anti virus lozenge - Google Patents
Multifunctional anti virus lozenge Download PDFInfo
- Publication number
- CN1640408A CN1640408A CN 200410015809 CN200410015809A CN1640408A CN 1640408 A CN1640408 A CN 1640408A CN 200410015809 CN200410015809 CN 200410015809 CN 200410015809 A CN200410015809 A CN 200410015809A CN 1640408 A CN1640408 A CN 1640408A
- Authority
- CN
- China
- Prior art keywords
- sialic acid
- buccal tablet
- mixture
- sialic
- mass percent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a multifunctional antiviral lozenge. It comprises filling agent, mucilage and sweetener as coventional ingredient of lozenge, and it is characterized by that it also contains (by mass percent) 0.05-10% of sialic acid or its derivative, and also contains 0.1-3% of plant extract. Said plants include the Chinese medicinal materials of ginseng, fresh ginger, sporobolus, mushroom, astragatus root, lonicera flower, garlic bulb. American ginseng or tea. Said lozenge has the effects of preventing virus infection and resisting common cold, and cleaning oral cavity.
Description
Technical field
The present invention relates to a kind of health care medicine buccal tablet technical field, especially relate to clean oral cavity, prevent the buccal tablet technical field of viral infection and anti-flu effect.
Background technology
The medicine buccal tablet is because be easy to carry, easy to use, advantages such as determined curative effect, a large amount of uses on medicine, have been obtained, as the siren buccal tablet, the blood sugar lowering buccal tablet, watermelon crystal buccal tablet or the like, as number of patent application is that 03119520.2 Chinese patent has been reported " glycyrrhiza compound buccal tablet and preparation method thereof ", this buccal tablet has been given full play to the clinical efficacy of FUFANG GANCAO PIAN, played the eliminating phlegm and relieving cough antiinflammation effectively, and the moistening throat of stimulation trachea body of gland secreting gland liquid, trachea, the dilution sputum, spuing of favourable sputum, and there are effects such as direct anti-inflammation and sterilization the throat part, thereby realize that clinical effectiveness swallows; Number of patent application is 03101266.3 Chinese patent " the two anti-buccal tablets of Radix Rhodiolae ", and it mainly is anti-hypoxia, radioprotective, eliminates organism fatigue, blood fat reducing, regains one's vigor rapidly, nourishing and fit keeping function and enhance immunity; Also have buccal tablets such as siren buccal tablet, watermelon crystal buccal tablet, they mainly are to be used for the auxiliary treatment laryngopharyngeal diseases.
Comprehensively above-mentioned, present most of buccal tablets do not have antiviral, anti-flu basically, improve the effect of intelligence, can't suppress the absorption of virus in human body upper respiratory tract and oral cavity.After during the opposite process SARS, people need a kind of energy antiviral convenient to use, the buccal tablet of anti-flu especially, it is oral that it can be fit to human body at any time, make the oral cavity cleaning, can produce tangible interception to virus absorption simultaneously, make human body produce the effect of necessary antiviral and anti-flu, reduce infected chance, particularly especially suitable to the young men and women of appointment.In addition, traditional buccal tablet function ratio is more single, mainly is to be used for clean oral cavity or treatment laryngopharyngeal diseases, has significant limitation, and consumer objects is fewer, and market is narrow.
Modern humans's life can't be avoided and viral contacting, especially in the city.World Health Organization (WHO) thinks that it is dangerous greatly to the human health tool that leap animal kind circle infects human uncertain virus.Once be exactly the example of crossing over animal kind circle viral infection in China and the popular SARS in other countries and regions.Doctor Heymann of infectious disease office of World Health Organization (WHO) thinks: the threat to the human health maximum is to have breaking out of fatefulue influenza virus.Doctor Heymann points out: if SARS virus is to belong to influenza virus, what its dead number will be than SARS death is total much more.One major defect of present existing antiviral drugs is because it all is the chemical compound by chemosynthesis, and body is all had adverse side effect.And it is as drug use, and its mechanism is to suppress the absorption of virus at cell surface, and when have been found that disease again the medication viral absorption of disinthibiting come too late.So, be not have specific drug basically to viral infection in the world at present, the medicine of clinical use in fact just helps body recovery.Chinese medicine has certain inhibitory action to virus, but also is being theoretically unsound aspect the drug mechanism of molecular level.At present the antiviral class chemicals that uses of China has two kinds of amantadine and rimantadines.Diamantane (obsolete) amine medicine can resist influenza A virus, stops virus to enter in the cell, and can change the hemagglutinin configuration, thereby resist the virus assembling.Though diamantane (obsolete) amine medicine can be treated influenza targetedly, but this type of medicine is only effective to influenza A virus, and the same with other all chemicalses, its side effect very obviously can produce tangible nervousness, anxiety, hallucination, the multisystem toxic reactions such as reaching the heart rate disorder of feeling sick as the user.So diamantane (obsolete) amine medicine is not widely accepted.Therefore, a kind of can resist viral infection make things convenient for health product or medicine to ensureing that the people's is healthy most important.
Summary of the invention
Technical problem to be solved by this invention is to design a kind of multi-functional antivirus buccal tablet at the existing problem of existing background technology, it plays the effect of the anti-flu of prophylaxis of viral infections, particularly influenza emits, also can improve the absorbability of intestinal for vitamin and mineral, improve the brain learning ability, help to improve body constitution and intelligence development level for student and this buccal tablet of young life-time service especially, simultaneously can clean oral cavity.
The present invention solves the problems of the technologies described above the technical scheme that is adopted: by the combined sorting and the prescription comprehensive Design of existing medicine and natural food raw material etc. are invented a kind of multi-functional antivirus buccal tablet, it comprises the filler of the common component of buccal tablet and mucilage, sweeting agent, can also contain flavouring agent in the time of necessary, it is characterized in that also containing the sialic acid with antiviral function or the sialic acid derivative of 0.05-10% mass percent.
Useful is, the preferred 0.1-8% mass percent of above-mentioned sialic acid or sialic acid derivative content, be lower than 0.1% o'clock product at the content of sialic acid or sialic acid derivative and will do not have the function of good prevention virion in cell surface absorption, there is no need and cost is too high when its content surpasses 8%, so both helped digesting and assimilating of human body, economy is not wasted again.The present invention finds that sialic acid or sialic acid derivative content better choice scope are the 0.2-5% mass percent, can play significant antiviral effect after by a large amount of prescription comprehensive Design and functional study.
The fact of being found according to the present invention, above-mentioned filler can be selected a kind of in starch syrup, microcrystalline Cellulose, dextrin, lactose, sucrose, glucose or other the edible filleies or their mixture for use.
Above-mentioned mucilage is a kind of of pectin, gelatin, arabic gum, sodium alginate, carrageenan or their mixture.
Above-mentioned sweeting agent is lactose, sucrose, glucose, glucide, other synthetic a kind of of sweeting agent or their mixture of eating.
Above-mentioned sialic acid is the sialic mixture of various differences that following sialic acid molecule general formula is had, and it can exist with free type monomeric form,
Wherein: R
4, R
7Can be H-, or CH
3CO-; R
5Can be CH
3-or HOCH
2-; R
8Can be H-, CH
3CO-, CH
3CH (OH) CO-, CH
3-or SO
3H-; R
9Can be H-, CH
3CO-, CH
3CH (OH) CO-or PO
3H
2-.Certainly the sialic mixture of various differences that above-mentioned sialic acid or sialic acid derivative also can be had for above-mentioned sialic acid molecule general formula, it to be existing by covalently bound form with protein, polypeptide or other saccharide, even exists with free type monomer and with protein, polypeptide or other saccharide form by the covalent bond mixture.
What be highly profitable is, above-mentioned component also contains the water soluble plant extract of mass percent 0.1-3%, this plant includes Radix Ginseng, Rhizoma Zingiberis Recens, Salvia japonica Thunb., mushroom, the Radix Astragali, Flos Lonicerae, Bulbus Allii, Radix Panacis Quinquefolii or Folium Camelliae sinensis, they can use also mutually separately, and compatibility uses, thereby being contained in the Nidus collocaliae acid composition that can improve in the oral cavity in mouth mucus and the body fluid and dynamic equilibrium and producing synergism with water soluble plant extract, this product has stronger antiviral effect, it makes full use of the marrow of the traditional Chinese medical science, utilize the elite of natural plants, the science of carrying out compatibility, make blending the east and the west, control foster combination, reach the determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs effect, so antiviral (comprising cold virus) better effects if.The main effect of plant extract is the human body immunity improving ability, and wherein discrete component has the effect that suppresses cold virus simultaneously.
Compared with prior art, the invention has the advantages that: the Nidus collocaliae acid formal name used at school that this buccal tablet mainly contains one of effective constituent is sialic acid (Sialic acid), being the Main Ingredients and Appearance of biologically active in Chinese traditional cuisines Nidus collocaliae, also is that female Ruzhong just provides one of necessary important component of early growth and development to the baby.Nidus collocaliae acid is a neuraminic acid, and its general formula of molecular structure is as shown below,
Wherein: R
4, R
7Can be H-, or CH
3CO-; R
5Can be CH
3-or HOCH
2-; R
8Can be H-, CH
3CO-, CH
3CH (OH) CO-, CH
3-or SO
3H-; R
9Can be H-, CH
3CO-, CH
3CH (OH) CO-or PO
3H
2-.Extensively be present in animal tissue and the microorganism, it is the important component part of epicyte protein, participate in the cell surface different physiological roles, playing important effect aspect adjusting Human Physiology, the biochemical function, Nidus collocaliae acid can promote the information transmission speed of brain nervous cell, the Nidus collocaliae acid content of neuron membrane is 20 times of other cell, and the Nidus collocaliae acid content in the human brain cell is 2-4 times of other animal, so the mankind can dominate the world.Animal test results shows: additional Nidus collocaliae acid can increase ganglion cerebri glucosides level and improve intelligence.Zelanian scientists is once tried the child to 1025 and is carried out the follow-up study in 18 years by a definite date from be born to graduating from the high school, and finds that Nidus collocaliae acid can improve child's early intelligence level of development, so contain the intelligence development that can help human body with this buccal tablet for a long time.Nidus collocaliae acid in the breast milk provides immunity for baby's early growth, and improves the absorbability of intestinal for vitamin and mineral.Because Nidus collocaliae acid can not degraded by digestive enzyme by digestive system the time, can enter the absorption that intestinal stops pathogenic entero becteria and virus and cell by digestive tract, play an important role to resisting multiple pathogenic bacteria, contain for a long time can improve human body with this buccal tablet with absorbability and immunity.The Nidus collocaliae acid pair cell has protection and Stabilization: Nidus collocaliae acid can prevent that with combining of epicyte protein these biomacromolecules are by the degraded of extracellular protease.France one seminar discovers that recently extracellular sialic acid can promptly be integrated the level of CMP-NeuAc in absorption and the irritation cell by human body cell.Therefore, the sialic acid of oral absorption has positive regulating action to the sialic acid dynamic equilibrium in the body fluid, can delay cell surface sialic acid detach procedure.Free Nidus collocaliae acid can stop the absorption of virion at cell surface in the body fluid: result of study proves, the monomer sialic acid of the dissolved state of several mM solubility just can form with the hemagglutinin of virus surface and combine in the body fluid, thereby suppresses the absorption of A type cold virus at cell surface effectively.Mechanism according to the cold virus invasion, scientist studies and has developed anti-cold virus medicine based on sialic acid derivative to stoping virion in the absorption of cell surface since the eighties in 20th century, can make human body produce necessary antiviral and anti-effect of catching a cold so contain with this buccal tablet, inhibited thereby this product is contained in the Nidus collocaliae acid concentration that can improve in the oral cavity in mouth mucus and the body fluid to the absorption of virion; Thereby this product be contained in can improve the Nidus collocaliae acid concentration in mouth mucus and the body fluid in the oral cavity and change mouth mucus and body fluid in the composition of different Nidus collocaliae acid inhibited to the absorption of virion; Thereby this product is contained in the Nidus collocaliae acid composition and the dynamic equilibrium that can improve in the oral cavity in mouth mucus and the body fluid has antivirus action; This product has antiviral and other biological function.Thereby this product be contained in the Nidus collocaliae acid composition that can improve in the oral cavity in mouth mucus and the body fluid and dynamic equilibrium and with water soluble plant extract produce synergism have certain antibiotic with clean the teeth anti-Zhu tooth function, make this buccal tablet also have the effect of clean oral cavity, the youngster that is particularly suitable in love uses.In addition, this buccal tablet also contains abundant edible protein and polypeptide, has high nutritive value.Comprehensively above-mentioned, the present invention is on the basis of the further investigation of the mechanism that virus and cell surface is formed absorption, discovery Nidus collocaliae acid can be processed into the buccal tablet form often take with resist virus infection, because it all is to extract from the edible raw material that the present invention contains bioactive Main Ingredients and Appearance, safe and reliable, nutrition good, taking convenience, do not have toxic and side effects and can be used as health care prevention product to take for a long time, so this buccal tablet anti-good buccal tablet of catching a cold that is a kind of multi-functional antiviral.
The specific embodiment
Embodiment describes in further detail the present invention below in conjunction with accompanying drawing.These examples only are further to introduce concrete ins and outs of the present invention, but do not limit spirit of the present invention and scope.
Embodiment 1
Buccal tablet contains:
Sialic acid 2.8%
Starch syrup (38DE) 6.0%
Sucrose 8.0%
Protein and polypeptide 81%
Pectin 2.0%
Mint flavouring 0.2%
Every 0.8 gram can repeatedly be obeyed/eat in one day.According to this recipe design, this buccal tablet should belong to the category of health food, and many clothes do not have secondary face to human body and ring, and the suggestion consumption is in every day below 20, and following example is as the same.
Embodiment 2
Buccal tablet contains:
Sialic acid 1%
Starch syrup (38DE) 3.0%
Protein and polypeptide 83%
Sucrose 9%
Radix Panacis Quinquefolii extract 1%
Arabic gum 2.7%
Spice 0.3%
The antiviral effect of this buccal tablet is listed in table-1.
Embodiment 3
Buccal tablet contains:
Sialic acid derivative (with polypeptide conjunction type Nidus collocaliae acid) 5%
Protein and polypeptide 78%
Starch syrup (38DE) 3.0%
Glucose 9%
Flos Lonicerae extract 0.6%
Radix Panacis Quinquefolii extract 1.2%
Arabic gum 3%
Spice 0.2%
The antiviral effect of this buccal tablet is listed in table-1.
Embodiment 4
Buccal tablet contains:
Sialic acid derivative (with polypeptide conjunction type Nidus collocaliae acid) 5.8%
Radix Astragali extract 0.5%
Folium Camelliae sinensis extract 0.5%
Protein and polypeptide 76%
Starch syrup (38DE) 6%
Glucose 8%
Arabic gum 3%
Spice 0.2%
The antiviral effect of this buccal tablet is listed in table-1.
This paper has also done the antiviral and the cell toxicity test of Nidus collocaliae acid buccal tablet:
Virus: A type influenza virus, StrainPR8;
Chief cell: mdck cell (ATCC#CCL34) Canine nephrocyte.
Cell growth medium and viral growth culture medium do not contain necessary aminoacid and third cave acid sodium, contain the 50ug/ml gentamycin.
Test to determine antiviral vitality with mdck cell CPE and hemagglutinin, influenza virus A is determined best antiviral test inoculum concentration by titration.
Cytotoxicity contrast: add each diluted concentration of test reagent but do not insert virus and determine whether this reagent itself influences cell and grow.Cytotoxicity is judged by microexamination.
Negative control: the test agent of neither adding an examination of during cell culture does not insert virus yet.
Viral growth assessment is adopted the pathogenic change effect of mdck cell and last a kind of cytotoxicity control method of culture fluid is used for guarantee test reagent pair cell and is free from side effects.If virus is not growth in mixture, it is effective that this mixture just is judged as under experiment condition the antagonism influenza virus A, and prerequisite is that this mixture pair cell does not have toxicity.If cytotoxicity is observed, antivirus action can not be assessed, and the rule of vigor test is that each cultivation can only be that positive or negative calculates, not part score.
Table-1: the antiviral of Nidus collocaliae acid buccal tablet and cell toxicity test result (being incubated 4 days)
| Sample | Extension rate | Human cold virus A challenge test | Controlled trial (virus-free) | ||
| Cytotoxicity | Agglutination test | Cytotoxicity | Agglutination test | ||
| Example two | ????10 | Can't see * clearly | Do not have | Can't see * clearly | Do not have |
| ????20 | Do not have | Do not have | Do not have | Do not have | |
| ????40 | Do not have | Do not have | Do not have | Do not have | |
| Example three | ????10 | Can't see * clearly | Do not have | Can't see * clearly | Do not have |
| ????20 | Do not have | Do not have | Do not have | Do not have | |
| ????40 | Do not have | Do not have | Do not have | Do not have | |
| Example four | ????10 | Can't see * clearly | Do not have | Can't see * clearly | Do not have |
| ????20 | Slightly | Do not have | Slightly | Do not have | |
| ????40 | Do not have | Do not have | Do not have | Do not have | |
| Do not add buccal tablet | Have | Have | Do not have | Do not have | |
*Can't see clearly is because reagent concentration Gao Suozhi too.
Antiviral and cell toxicity test result show that the Nidus collocaliae acid buccal tablet has tangible antivirus action.
Embodiment 5
Buccal tablet contains:
Sialic acid derivative (with polypeptide conjunction type Nidus collocaliae acid) 8%
Bulbus Allii extract 0.1%
Protein and polypeptide 75%
Starch syrup (38DE) 6%
Glucose 7.7%
Arabic gum 3%
Spice 0.2%
Embodiment 6
Buccal tablet contains:
Sialic acid derivative (with polypeptide conjunction type Nidus collocaliae acid) 0.1%
Bulbus Allii extract 3%
Protein and polypeptide 78%
Starch syrup (38DE) 6%
Glucose 7.6%
Gelatin 5%
Spice 0.3%
Embodiment 7
Buccal tablet contains:
Sialic acid derivative (with polypeptide conjunction type Nidus collocaliae acid) 0.2%
Bulbus Allii extract 2%
Agaricus campestris extract 1%
Protein and polypeptide 78%
Starch syrup (38DE) 6%
Glucose 7.6%
Carrageenan 5%
Spice 0.2%
Claims (10)
1, a kind of multi-functional antivirus buccal tablet, it comprises filler, mucilage and the sweeting agent of the common component of buccal tablet, can also contain flavouring agent in the time of necessary, it is characterized in that also containing the sialic acid or the sialic acid derivative of the tool antivirus action of 0.05-10% mass percent.
2, buccal tablet according to claim 1 is characterized in that described sialic acid or sialic acid derivative content are the 0.1-8% mass percent.
3, buccal tablet according to claim 1 is characterized in that described sialic acid or sialic acid derivative content are the 0.2-5% mass percent.
4,, it is characterized in that described filler is a kind of in starch syrup, microcrystalline Cellulose, dextrin, lactose, sucrose, glucose, other edible filleies or their mixture according to the described any buccal tablet of claim 1 to 3.
5,, it is characterized in that described mucilage is a kind of of pectin, gelatin, arabic gum, sodium alginate, carrageenan or their mixture according to the described any buccal tablet of claim 1 to 3.
6,, it is characterized in that described sweeting agent is lactose, sucrose, glucose, glucide, other synthetic a kind of of sweeting agent or their mixture of eating according to the described any buccal tablet of claim 1 to 3.
7, according to the described any buccal tablet of claim 1 to 3, it is characterized in that described component also contains the water soluble plant extract of mass percent 0.1-3%, this plant includes Radix Ginseng, Rhizoma Zingiberis Recens, Salvia japonica Thunb., mushroom, the Radix Astragali, Flos Lonicerae, Bulbus Allii, Radix Panacis Quinquefolii or Folium Camelliae sinensis, and they can use also compatibility use mutually separately.
8, according to the described any buccal tablet of claim 1 to 3, it is characterized in that described sialic acid is the sialic mixture of various differences that following sialic acid molecule general formula is had, it can exist with free type monomeric form, wherein: R
4, R
7Can be H-, or CH
3CO-; R
5Can be CH
3-or HOCH
2-; R
8Can be H-, CH
3CO-, CH
3CH (OH) CO-, CH
3-or SO
3H-; R
9Can be H-, CH
3CO-, CH
3CH (OH) CO-or PO
3H
2-.
9, according to the described any buccal tablet of claim 1 to 3, it is characterized in that described sialic acid or sialic acid derivative are the sialic mixture of various differences that following sialic acid molecule general formula is had, it is to exist with protein, polypeptide or the covalently bound form of other saccharide, wherein: R
4, R
7Can be H-, or CH
3CO-; R
5Can be CH
3-or HOCH
2-; R
8Can be H-, CH
3CO-, CH
3CH (OH) CO-, CH
3-or SO
3H-; R
9Can be H-, CH
3CO-, CH
3CH (OH) CO-or PO
3H
2-.
10, according to the described any buccal tablet of claim 1 to 3, it is characterized in that described sialic acid or sialic acid derivative are the sialic mixture of various differences that following sialic acid molecule general formula is had, it reaches with free type monomer and the form of protein, polypeptide or other saccharide covalent bond mixture exists, wherein: R
4, R
7Can be H-, or CH
3CO-; R
5Can be CH
3-or HOCH
2-; R
8Can be H-, CH
3CO-, CH
3CH (OH) CO-, CH
3-or SO
3H-; R
9Can be H-, CH
3CO-, CH
3CH (OH) CO-or PO
3H
2-.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410015809 CN1640408A (en) | 2004-01-11 | 2004-01-11 | Multifunctional anti virus lozenge |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410015809 CN1640408A (en) | 2004-01-11 | 2004-01-11 | Multifunctional anti virus lozenge |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1640408A true CN1640408A (en) | 2005-07-20 |
Family
ID=34868111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410015809 Pending CN1640408A (en) | 2004-01-11 | 2004-01-11 | Multifunctional anti virus lozenge |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1640408A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104041827A (en) * | 2014-06-30 | 2014-09-17 | 江苏布诺堂健康生物科技有限公司 | Microcapsule containing sialic acid and DHA and preparation method thereof |
| CN104586642A (en) * | 2015-02-06 | 2015-05-06 | 武汉中科光谷绿色生物技术有限公司 | Applications of N-acetvlneuraminic acid monomer, N-acetvlneuraminic acid hydrate or N-acetvlneuraminic acid salt in personal care supplies |
| CN106215169A (en) * | 2016-08-10 | 2016-12-14 | 海安葛莱森生物科技有限公司 | The buccal tablet of flu-prevention virus and application thereof |
| WO2021249501A1 (en) * | 2020-06-11 | 2021-12-16 | 广东盛普生命科技有限公司 | Antiviral preparation |
| CN115644438A (en) * | 2022-11-04 | 2023-01-31 | 中华全国供销合作总社济南果品研究所 | A buccal tablet containing radix Panacis Quinquefolii and fructus fici for refreshing mind and improving intelligence, and its preparation method |
-
2004
- 2004-01-11 CN CN 200410015809 patent/CN1640408A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104041827A (en) * | 2014-06-30 | 2014-09-17 | 江苏布诺堂健康生物科技有限公司 | Microcapsule containing sialic acid and DHA and preparation method thereof |
| CN104041827B (en) * | 2014-06-30 | 2016-06-15 | 南京极燕生物科技有限公司 | A kind of microcapsule containing sialic acid and DHA and preparation method thereof |
| CN104586642A (en) * | 2015-02-06 | 2015-05-06 | 武汉中科光谷绿色生物技术有限公司 | Applications of N-acetvlneuraminic acid monomer, N-acetvlneuraminic acid hydrate or N-acetvlneuraminic acid salt in personal care supplies |
| CN106215169A (en) * | 2016-08-10 | 2016-12-14 | 海安葛莱森生物科技有限公司 | The buccal tablet of flu-prevention virus and application thereof |
| WO2021249501A1 (en) * | 2020-06-11 | 2021-12-16 | 广东盛普生命科技有限公司 | Antiviral preparation |
| CN115644438A (en) * | 2022-11-04 | 2023-01-31 | 中华全国供销合作总社济南果品研究所 | A buccal tablet containing radix Panacis Quinquefolii and fructus fici for refreshing mind and improving intelligence, and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1701789A (en) | Nutrition replenisher containing sialic acid and its derivative | |
| CN1927383A (en) | Compound recipe preparation for lowering oxidative stress rapidly and prepn. method therefor | |
| CN101041009A (en) | Chinese traditional medicine compound for treating faucitis | |
| CN103083510A (en) | Chinese medicinal oral liquid for improving poultry immune function and its preparation method | |
| CN1314387C (en) | Children cough and asthma treating Chinese traditional medicine and its preparation | |
| CN104491038B (en) | Traditional Chinese medicine oral liquid for treating calf diarrhea and preparation method of traditional Chinese medicine oral liquid | |
| CN1640408A (en) | Multifunctional anti virus lozenge | |
| CN104739964B (en) | A kind of snail sobering preparation and preparation method thereof | |
| CN113769029B (en) | Medicinal and edible herbal composition for improving intestinal absorption and immune function | |
| CN105920606A (en) | Compound oral liquid for treating children diarrhea and preparation method thereof | |
| CN101972325A (en) | Medicament composition for treating chick coccidiosis and preparation method thereof | |
| CN111011596A (en) | Traditional Chinese medicine composition for replacing preventive antibiotics in meat duck breeding and application thereof | |
| CN106937966B (en) | Stomach nourishing paste and preparation method thereof | |
| CN1903240A (en) | Medicinal use of Aralia continentalis kitag | |
| CN111067108A (en) | Rose tartary buckwheat polypeptide oral liquid and preparation method thereof | |
| CN1476836A (en) | Anti-SARS action of zizhuisongguo chrysanthemum extract and its medicine composition | |
| CN1939344A (en) | Donkey-hide gelatin oral preparation and its making method | |
| CN103893240A (en) | Composition for preventing and/or treating respiratory system diseases caused by hazes | |
| CN105168292B (en) | A kind of relieving cough and asthma veterinary medical composition and preparation method thereof | |
| CN1840008A (en) | Chinese medicinal granule for clearing pharynx and moistening throat and preparation method thereof | |
| CN103705533B (en) | Pharmaceutical composition of preventing and treating poultry infectious disease and its preparation method and application | |
| CN103844136A (en) | Special healthcare Chinese herbal medicinal feed of free-range chickens | |
| CN1520863A (en) | Formula and dosage form of oral preparation with Bulbus Lilii as main material for lung health promotion, skin caring and kidney invigorating | |
| CN107594240A (en) | Peptide fruit juice that a kind of preventing cold peptide compounds with pear juice and preparation method thereof | |
| CN1299707C (en) | Yinhuang oral liquor and its producing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |